Pyrazinamide resistance in rifampicin discordant tuberculosis.

Nomonde Ritta MvelaseRavesh SinghKhine Swe Swe-HanKoleka Patience Mlisana

Published in: PloS one (2022)

Given the low prevalence of pyrazinamide resistance in rifampicin discordant TB, this anti-TB drug still has a significant role in the treatment of these patients. Performing pyrazinamide susceptibility testing remains a challenge, our findings show that isoniazid susceptible isolates are unlikely to be resistant to pyrazinamide among the discordant TB isolates.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
risk factors
genetic diversity
prognostic factors
emergency department
combination therapy
drug induced
hiv aids